Welcome to our dedicated page for Electrocore news (Ticker: ECOR), a resource for investors and traders seeking the latest updates and insights on Electrocore stock.
electroCore, Inc. reports developments in bioelectronic medicine and wellness products built around non-invasive vagus nerve stimulation, or nVNS. Company news commonly covers prescription gammaCore for migraine, Quell Fibromyalgia, Truvaga and Truvaga Plus consumer wellness products, and TAC-STIM for human performance.
Recurring updates include financial results, U.S. prescription sales activity, direct-to-consumer wellness sales, product-line commercialization, clinical research involving gammaCore nVNS, and participation in healthcare and investor conferences. News also highlights applications of vagus nerve stimulation across prescription medical uses and consumer wellness settings.
electroCore (Nasdaq: ECOR) reported second quarter 2026 net sales of $9.5 million, up about 28% from $7.4 million a year earlier, led by U.S. VA prescription gammaCore and direct-to-consumer Truvaga, plus strong Quell Fibromyalgia uptake.
Quell sales reached $1.3 million, growing roughly 700% year-over-year and 30% sequentially, with cumulative Quell revenue of about $4.0 million since May 2025. Truvaga revenue was $1.3 million, up 27% year-over-year but down 17% sequentially after reduced marketing spend. VA gammaCore revenue grew about 11% year-over-year, with approximately 16,400 VA patients treated, or 2.7% estimated VA headache market penetration.
Gross profit rose to $8.2 million, though gross margin slipped to 86.5% from 87.3% on higher inventory reserves. GAAP net loss narrowed to $3.1 million (–$0.33 per share) from $3.7 million (–$0.44), and adjusted EBITDA net loss improved to $1.8 million from $2.4 million. Cash, cash equivalents, and marketable securities totaled about $10.0 million at June 30, 2026. The company raised 2026 revenue guidance to more than 30% growth over 2025 and targets positive adjusted EBITDA in Q3 2027, supported by commercial reorganization, expanded VA-focused sales coverage, and expected reductions in sales, marketing, and transaction-related expenses.
electroCore (Nasdaq: ECOR) announced that management will participate in two August 2026 investor conferences. The company will attend the Needham 11th Annual Virtual MedTech and Diagnostics Conference on August 11, 2026, hosting virtual one-on-one meetings, and the Canaccord Genuity 46th Annual Growth Conference in Boston on August 11–12, 2026.
electroCore (Nasdaq: ECOR) will report financial results for the second quarter ended June 30, 2026, after the market close on Thursday, August 6, 2026. Management will host a results webinar at 4:30 PM EDT, with investor access via phone dial-in, webinar ID, passcode, and an online registration link.
electroCore (Nasdaq: ECOR) announced the publication of a peer-reviewed narrative review, “Two Paths to the Body's Superhighway—The Auricular Branch (taVNS) and the Cervical Bundle (tcVNS),” in Frontiers in Neuroscience. Authored by electroCore’s Chief Medical Officer Peter S. Staats and Senior Director of Medical Affairs Justyna Blake, the article compares transcutaneous auricular and cervical vagus nerve stimulation approaches.
The review summarizes current scientific literature on anatomical targets, mechanisms of action, clinical evidence, safety, and therapeutic potential. It highlights a growing body of published research supporting cervical vagus nerve stimulation (tcVNS) as a clinically validated non-invasive vagus nerve stimulation modality, while emphasizing that both cervical and auricular methods remain important and continue to evolve with ongoing research.
electroCore (Nasdaq: ECOR) announced that a review article on cervical non-invasive vagus nerve stimulation (nVNS) has been accepted by Frontiers in Neuroscience.
The article synthesizes decades of multidisciplinary evidence that cervical nVNS can activate vagal pathways without surgery and addresses skepticism about non-invasive vagal activation.
electroCore (Nasdaq: ECOR) will present at Planet MicroCap Las Vegas 2026 Powered by MicroCapClub at the Bellagio in Las Vegas.
Interim President and CFO Joshua Lev will give a company presentation and host one-on-one investor meetings, with a webcast and recent strategy video available online.
electroCore (Nasdaq: ECOR) announced publication in JAMA Network Open of a cluster randomized clinical trial evaluating a modified Quell device added to outpatient physical therapy for fibromyalgia.
Among 384 participants, PT-Quell showed greater pain and fatigue improvements, with benefits seen by 30 days and lasting up to six months.
electroCore (NASDAQ: ECOR) will present at the LD Micro Invitational XVI conference in Los Angeles on May 18, 2026. Interim President and CFO Joshua Lev will deliver the company presentation at 10:30 am PT and hold one-on-one investor meetings; a webcast is available.
electroCore (Nasdaq: ECOR) reported Q1 2026 net sales of $9.6 million, up ~43% year‑over‑year, with 87% gross margin and GAAP net loss of $5.3 million. Adjusted EBITDA net loss improved 24% to $2.3 million. The VA remained the largest channel; Quell and Truvaga contributed growth. The company reaffirmed ~30% full‑year 2026 revenue growth guidance and reported cash and marketable securities of $8.8 million at March 31, 2026.
electroCore (Nasdaq: ECOR) announced on April 30, 2026 that TAC-STIM, its handheld non-invasive vagus nerve stimulation wellness product for human performance, was named a national semifinalist in the National Safety Council 2026 Work to Zero Safety Innovation Challenge.
TAC-STIM, developed with the U.S. Air Force Research Laboratory, is deployed across multiple U.S. military commands and will be presented at the NSC Safety Summit on May 7–8, 2026; semifinalists may access the Work to Zero Pilot Grant Program.